Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period.

[1]  P. De Wals,et al.  Effectiveness of Pneumococcal Conjugate Vaccine Using a 2+1 Infant Schedule in Quebec, Canada , 2010, The Pediatric infectious disease journal.

[2]  K. O'Brien,et al.  Revisiting Pneumococcal Carriage by Use of Broth Enrichment and PCR Techniques for Enhanced Detection of Carriage and Serotypes , 2010, Journal of Clinical Microbiology.

[3]  W. Schaffner,et al.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. , 2010, The Journal of infectious diseases.

[4]  W. Schaffner,et al.  Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. , 2008, The Journal of infectious diseases.

[5]  B. Schwartz,et al.  Uptake of pneumococcal conjugate vaccine among children in the 1998-2002 United States birth cohorts. , 2008, American journal of preventive medicine.

[6]  W. Schaffner,et al.  Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. , 2007, The Journal of infectious diseases.

[7]  K. Wolter,et al.  Effect of Vaccine Shortages on Timeliness of Pneumococcal Conjugate Vaccination: Results From the 2001–2005 National Immunization Survey , 2007, Pediatrics.

[8]  Susan S. Huang,et al.  Emergence of 19A as Virulent and Multidrug Resistant Pneumococcus in Massachusetts Following Universal Immunization of Infants With Pneumococcal Conjugate Vaccine , 2007, The Pediatric infectious disease journal.

[9]  D. Rasko,et al.  Impact of the Pneumococcal Conjugate Vaccine on Serotype Distribution and Antimicrobial Resistance of Invasive Streptococcus pneumoniae Isolates in Dallas, TX, Children From 1999 Through 2005 , 2007, The Pediatric infectious disease journal.

[10]  W. Schaffner,et al.  Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study , 2006, The Lancet.

[11]  B. Mahon,et al.  Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. , 2006, Vaccine.

[12]  K. O'Brien,et al.  Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination. , 2006, Vaccine.

[13]  M. Lipsitch,et al.  Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. , 2005, The Journal of infectious diseases.

[14]  P. Mäkelä,et al.  Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. , 2004, The Journal of infectious diseases.

[15]  L. Harrison,et al.  Active bacterial core surveillance of the emerging infections program network. , 2001, Emerging infectious diseases.

[16]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children , 2000, The Pediatric infectious disease journal.

[17]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. , 2000, The Pediatric infectious disease journal.

[18]  C. Broome,et al.  Pneumococcal Disease after Pneumococcal Vaccination , 1980 .

[19]  C. Broome,et al.  Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. , 1980, New England Journal of Medicine.